Dr. Daniel Amen shared his BRIGHTMINDS approach for preventing Alzheimer's, addressing 11 risk factors including blood flow, ...

Donanemab was approved by the FDA in July 2024 to treat adults with early symptomatic Alzheimer's disease with confirmed ...

Alzheimer’s disease continues to rise as one of the most pressing health challenges facing aging populations today. It ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

The research looked specifically at blood stem cells, which live in the bone marrow and make different types of blood cells.

It's been recognized for some time that Alzheimer's disease affects brain regions differently and that tau - a protein known ...

Many in the MAGA movement are in a state of anger and disbelief over the Justice Department and FBI’s memo disclosing that ...

Using brain gene expression maps from the Allen Human Brain Atlas, the researchers tested the degree to which Alzheimer’s risk genes explain the patterns of both actual and residual tau. This allowed ...

Treating the neurodegenerative disease in its earlier stages is key to slowing cognitive decline. A new study offers hope for ...

The earliest warning signs of Alzheimer's disease include memory loss that impacts your daily functioning, vision and ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...